A comparative study of ofloxacin and pivmecillinam in acute exacerbations of chronic bronchitis.
In a double-blind study in 84 patients with chronic bronchitis and purulent exacerbations, ofloxacin 200 mg b.i.d. and pivampicillin 700 mg t.i.d., were compared with respect to efficacy and safety. Both treatments resulted in a uniform and very high bacteriological elimination rate (94.1% to 97.2%) and clinical cure rate (97.4% to 97.6%). There were, however, signs of fewer adverse reactions and a better patient acceptance in the ofloxacin group.
Egede
F
F
Department of Chest Medicine, University Hospital, Odense, Denmark.
Kristensen
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000561:Amdinocillin Pivoxil / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D012074:Remission Induction
D000561:Amdinocillin Pivoxil; D015242:Ofloxacin